MA38455A1 - Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin - Google Patents

Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin

Info

Publication number
MA38455A1
MA38455A1 MA38455A MA38455A MA38455A1 MA 38455 A1 MA38455 A1 MA 38455A1 MA 38455 A MA38455 A MA 38455A MA 38455 A MA38455 A MA 38455A MA 38455 A1 MA38455 A1 MA 38455A1
Authority
MA
Morocco
Prior art keywords
inflammatory bowel
bowel disease
pidotimodes
treat inflammatory
pidotimode
Prior art date
Application number
MA38455A
Other languages
English (en)
Other versions
MA38455B1 (fr
Inventor
Federico Mailland
Maurizio Caserini
Francesco Scarci
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MA38455A1 publication Critical patent/MA38455A1/fr
Publication of MA38455B1 publication Critical patent/MA38455B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur l'utilisation du pidotimode, ou d'un sel physiologiquement acceptable de celui-ci, pour traiter la maladie inflammatoire de l'intestin. Pour le traitement selon l'invention, le pidotimode ou un sel physiologiquement acceptable de celui-ci, peut être administré soit par voie orale soit par voie rectale.
MA38455A 2013-04-05 2013-04-05 Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin MA38455B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/057208 WO2014161595A1 (fr) 2013-04-05 2013-04-05 Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin

Publications (2)

Publication Number Publication Date
MA38455A1 true MA38455A1 (fr) 2017-12-29
MA38455B1 MA38455B1 (fr) 2018-05-31

Family

ID=48048059

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38455A MA38455B1 (fr) 2013-04-05 2013-04-05 Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin

Country Status (18)

Country Link
US (1) US20160058739A1 (fr)
EP (1) EP2981289A1 (fr)
JP (1) JP6122208B2 (fr)
KR (1) KR20150144743A (fr)
CN (1) CN105209072A (fr)
AU (1) AU2013385170A1 (fr)
BR (1) BR112015025296A2 (fr)
CA (1) CA2901338A1 (fr)
EA (1) EA201591930A1 (fr)
HK (1) HK1216150A1 (fr)
MA (1) MA38455B1 (fr)
MX (1) MX2015014061A (fr)
NI (1) NI201500147A (fr)
PH (1) PH12015502305A1 (fr)
SG (1) SG11201506509TA (fr)
TN (1) TN2015000433A1 (fr)
UA (1) UA113467C2 (fr)
WO (1) WO2014161595A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
PT1673092E (pt) * 2003-10-17 2007-11-23 4 Aza Ip Nv ''derivados de pteridina substituídos com heterociclos e sua utilização em terapia''
US20070032477A1 (en) * 2003-10-17 2007-02-08 Waer Mark J A Pteridine derivatives useful for making pharmaceutical compositions
CN101134034A (zh) * 2006-08-29 2008-03-05 江卫世 免疫促进药及其制备方法
US20090142769A1 (en) * 2007-11-29 2009-06-04 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for determining anti-TNF therapeutic response
CN101623499A (zh) * 2008-07-07 2010-01-13 杨喜鸿 抗生素和匹多莫德的药物组合物及其制备方法和药物应用
EP2923734B1 (fr) * 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Analogues de purines et leur utilisation en tant qu'agents immunosuppresseurs
CN102234313B (zh) * 2011-08-16 2013-02-27 青岛康地恩药业股份有限公司 一种匹多莫德的合成方法
CN102525903B (zh) * 2012-01-20 2014-07-30 江苏吴中医药集团有限公司 一种匹多莫德的口服液体制剂

Also Published As

Publication number Publication date
MA38455B1 (fr) 2018-05-31
BR112015025296A2 (pt) 2017-07-18
PH12015502305A1 (en) 2016-02-15
KR20150144743A (ko) 2015-12-28
AU2013385170A1 (en) 2015-09-24
CN105209072A (zh) 2015-12-30
NI201500147A (es) 2016-01-06
TN2015000433A1 (en) 2017-01-03
CA2901338A1 (fr) 2014-10-09
JP2016515591A (ja) 2016-05-30
MX2015014061A (es) 2016-04-07
WO2014161595A1 (fr) 2014-10-09
UA113467C2 (uk) 2017-01-25
EP2981289A1 (fr) 2016-02-10
US20160058739A1 (en) 2016-03-03
HK1216150A1 (zh) 2016-10-21
SG11201506509TA (en) 2015-10-29
JP6122208B2 (ja) 2017-04-26
EA201591930A1 (ru) 2016-02-29

Similar Documents

Publication Publication Date Title
FR24C1028I2 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EP3019491A4 (fr) Inhibiteurs de kinase pour le traitement d'une maladie
EP2683382A4 (fr) Régimes posologiques pour le traitement de la maladie de fabry
FR3004920B1 (fr) Dispositif d'osteotomie, en particulier pour la realisation du scarf extreme dans le traitement de l'hallux valgus severe.
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3049104A4 (fr) Compositions de vaccins, adjuvants et procédés pour le traitement d'infections urinaires
EP2978446A4 (fr) Procédés et agents pour le traitement de la maladie d'alzheimer
ME03374B (fr) Dérivés 5-[(pipérazine-1-yl) -3-oxo-propyl]-imidazolidine -2,4-dione comme inhibiteurs d'adamts pour le traitement de l'arthrose
EP2498603A4 (fr) Utilisation d'agents antibactériens pour le traitement d'affections de type épithélial
EP2827847A4 (fr) Complexes contenant du strontium administré par voie topique pour le traitement de la douleur, du prurit et de l'inflammation
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
MA53501A (fr) Inhibiteurs de pde9 pour le traitement de la drépanocytose
EP2579863A4 (fr) Composés pour le traitement de la mastite bovine
EP2900259A4 (fr) Schéma posologique de glycosidase pour le traitement d'une maladie infectieuse
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille
EP3829646A4 (fr) Nanoparticules thérapeutiques par complexation de coacervat et leur utilisation pour le traitement de bactéries
FR2977798B1 (fr) Utilisation de composes oligosaccharidiques pour la prevention et le traitement des cicatrices pathologiques
EP2981272A4 (fr) Silicate de zirconium microporeux et agents diurétiques pour la réduction du potassium et le traitement d'une maladie rénale chronique et/ou cardiaque chronique
MA38155A1 (fr) Utilisation du pidotimod pour traiter le psoriasis
MA38455B1 (fr) Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin
EP3368512A4 (fr) Dérivés d'indoline pour le traitement et/ou la prévention des maladies fibrotiques
MA39072A1 (fr) Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales